Compare Becton Dickinson and Co (BDX) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Phillips 66 — how do they compare? Becton Dickinson and Co trades at $149.95 (market cap $41.51B), while Phillips 66 trades at $201 (market cap $80.77B). The key difference: Phillips 66 is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | PSX | |
|---|---|---|
Market Cap | $41.51B | $80.77B |
Sector | Health | Energy |
52-Week High | $185.39 | $201.45 |
52-Week Low | $135.49 | $118.37 |
Enterprise Value | $57.97B | $102.74B |
Dividend Yield | 2.79% | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Phillips 66 (PSX) trades at $198.29, up 5.27% with strong technical momentum and bullish moving average signals. The stock shows solid fundamentals with a P/E of 19.59, P/S of 0.6, and ROE of 14.75%, though revenue declined from $170B in 2022 to $132.38B in 2025. Recent earnings beats and consistent dividends of $1.27 quarterly support investor confidence amid refining margin strength.
Outlook remains positive with analyst consensus at Buy (57%) and $201.50 target, though risks include volatile oil prices, declining revenue trends, and high RSI suggesting overbought conditions. The refining sector benefits from Middle East tensions, but execution on cost control and margin stability will dictate near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
